Tium Bio

Imara

This biopharmaceutical company develops oral small-molecule therapies to treat patients with rare genetic blood disorders, including sickle cell disease and beta thalassemia.

Velorum Therapeutics

This company develops heme-sequestering biologic drugs for patients with lung cancer, rare genetic porphyrias and heme-induced tissue injuries.

Oriva

This clinical-stage biotechnology company develops therapies for chronic gynecological diseases, including endometriosis and uterine fibroids, for women requiring non-hormonal or disease-modifying treatment options.

AgomAb Therapeutics

This biopharmaceutical company develops therapies to treat fibrotic and inflammatory diseases for patients with conditions such as Crohn's disease and pulmonary fibrosis.

Be Biopharma

This company develops engineered B cell medicines to treat patients with hemophilia B, genetic diseases, and cancer.

GondolaBio

This biopharmaceutical company develops clinical-stage and preclinical medicinal therapeutics for patients living with rare genetic diseases.

Immitra Bio

This company develops an in-vivo gene editing platform to provide off-the-shelf curative treatments for patients with rare genetic diseases.

Hemab Therapeutics

This biotechnology company develops prophylactic antibody-based therapies for patients with rare bleeding and thrombotic disorders such as Glanzmann thrombasthenia and von Willebrand disease.